MB-07133

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H21N4O8P
Molecular Weight	440.3444
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO[P@]3(=O)OCC[C@H](O3)C4=CC=NC=C4)[C@@H](O)[C@@H]2O

InChI

InChIKey=HOAHIHGOMCBTFW-XCJSNOFESA-N

InChI=1S/C17H21N4O8P/c18-13-3-7-21(17(24)20-13)16-15(23)14(22)12(28-16)9-27-30(25)26-8-4-11(29-30)10-1-5-19-6-2-10/h1-3,5-7,11-12,14-16,22-23H,4,8-9H2,(H2,18,20,24)/t11-,12+,14+,15-,16+,30-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C17H21N4O8P
Molecular Weight	440.3444
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8379682

Cytarabine ocfosfate (commercial name: Starasid) is a prodrug having stearyl group attached to phosphoric acid at 5' position of arabinose moiety of cytosine arabinoside (Ara-C). This drug is given orally. The mode of action is in the inhibition of DNA synthesis after conversion to Ara-CTP as in Ara-C. The drug is metabolized in the liver, producing the intermediate metabolite, C-C3PCA which is converted to Ara-C gradually. This property results in the maintenance of relatively long time the blood Ara-C levels. This was proved to be active clinically against acute leukemia and MDS.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA polymerase (alpha/delta/epsilon) 5 Target ID: CHEMBL2363042 Sources: http://www.rxlist.com/cytarabine-drug.htm \| http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Cytarabine_monograph_1May2014.pdf \| http://www.nature.com/leu/journal/v15/n6/full/2402114a.html	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Leukemia 87 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8379682 http://adisinsight.springer.com/drugs/800000884 https://www.ncbi.nlm.nih.gov/pubmed/12162758	Primary		Approved 8429	Starasid Approved Use cytarabine ocfosfate is used clinically in Japan for the treatment of leukemia or myelodysplastic syndrome. Launch Date 7.2308163E11
Myelodysplastic syndromes 58 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8379682 http://adisinsight.springer.com/drugs/800000884 https://www.ncbi.nlm.nih.gov/pubmed/12162758	Primary		Approved 8429	Starasid Approved Use cytarabine ocfosfate is used clinically in Japan for the treatment of leukemia or myelodysplastic syndrome. Launch Date 7.2308163E11

PubMed

Title	Date	PubMed
[A new antileukemic drug, cytarabine ocfosfate].	1993 Sep	8379682
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.	1996 Oct	8890711
[Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].	1998 Oct	9797816

Patents

Sample Use Guides

In Vivo Use Guide

For adult acute non-lymphatic leukemia: In general, for adults, take 2-6 capsules (100-300mg of the active ingredient anhydride) in 1-3 divided doses a day after meal. For myelodysplastic syndrome: In general, for adults, take 2-4 capsules (100-200mg of the active ingredient anhydride) in 1-3 divided doses a day after meal, for 2 to 3 weeks every day, then discontinue the medication for 2-3 weeks and repeat this schedule. The dosage may be adjusted according to your disease or symptoms.Strictly follow the instructions.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:15:41 UTC 2023` Edited by `admin` on `Fri Dec 15 16:15:41 UTC 2023`
Record UNII	BNL5ERR07R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MB-07133

Common Name

English

MB-7133

Common Name

English

4-AMINO-1-(5-O-((2R, 4S)-2-OXIDO-4-(4-PYRIDINYL)-1, 3, 2-DIOXAPHOSPHORINAN-2-YL)-.BETA.-D-ARABINOFURANOSYL)-2(1H)-PYRIMIDINONE

Common Name

English

2(1H)-PYRIMIDINONE, 4-AMINO-1-(5-O-((2R,4S)-2-OXIDO-4-(4-PYRIDINYL)-1,3,2-DIOXAPHOSPHORINAN-2-YL)-.BETA.-D-ARABINOFURANOSYL)-

Common Name

English

MB 07133 [WHO-DD]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/07/477